Clinical Trial Update: Study Evaluating SKI-606 in Subject With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating SKI-606 (sorafenib) in subjects with solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Sorafenib (SKI-606) (sorafenib)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Tumors | Phase 1 | Status: COMPLETED